NCT04917042

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Florida · Academic / Other
• Sex: All
• Age: 12 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.

Conditions

• Peripheral Nerve Sheath Tumor

Interventions

Type	Name	Description
DRUG	Tazemetostat	Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.

Timeline

• Start date: 2021-08-25
• Primary completion: 2025-02-14
• Completion: 2026-04-01
• First posted: 2021-06-08
• Last updated: 2026-02-04
• Results posted: 2026-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study